Evidence map›Paper›PMID 40541945›Full record

ReviewNPJ Parkinson's disease2025

A community-led initiative to de-risk and advance Parkinson's disease therapeutic targets.

Alexandra Vaiana, Jonathan Behr, Ryan Birol, Cornelis Blauwendraat, Bradford Casey, Kushan Chowdhury, Martin Citron, Joshua Crapser, Victoria Dardov, Fiona Ducotterd and 47 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

57 authors.

Alexandra VaianaThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Jonathan BehrSV Health Investors, Boston, MA, USA.
Ryan BirolThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Cornelis BlauwendraatCoalition for Aligning Science, Chevy Chase, MD, USA.
Bradford CaseyThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Kushan ChowdhuryBiotech Connection Bay Area, San Francisco, CA, USA.
Martin CitronUCB Pharma, Brussels, Belgium.
Joshua CrapserDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Victoria DardovTechnome, Herndon, VA, USA.
Fiona DucotterdUniversity College London, Great Britain, UK.
Sonya DumanisCoalition for Aligning Science, Chevy Chase, MD, USA.
John DunlopAliada Therapeutics, Boston, MA, USA.
Michelle DurborowThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Brian FiskeThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Jessica GoldenThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Jonas HannestadGain Therapeutics, Bethesda, MD, USA.
Wendy HungUniversity of California, San Franscisco, San Franscisco, CA, USA.
Jennifer KempStrategies for Open Science (Stratos), Santa Cruz, CA, USA.
Robin KleimanMyrobalan Therapeutics, Medford, MA, USA.
Adam KnightNeuro.VC, San Franscisco, CA, USA.
Andrew Koemeter-CoxThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Bruce LeuchterNeurvati Neurosciences, New York, NY, USA.
Bejamin A LogsdonCajal Neuroscience Inc., Seattle, WA, USA.
Rita MarreirosChan Zuckerberg Biohub, San Franscisco, CA, USA.
Julie E MillerDepartments of Neuroscience and Speech, Language and Hearing Sciences, University of Arizona, Tucson, AZ, USA.
Amanda MitchellIndependent Consultant, Seattle, WA, USA.
Pooja MukherjeeUniversity of California Berkeley, Department of Molecular and Cell Biology, Berkeley, CA, USA.
Grace NavarroThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Matthew R NelsonGenscience LLC, New York, NY, USA.
Karoly NikolichDepartment of Psychiatry, Stanford University School of Medicine, Stanford, CA, USA.
Tom OtisLario Therapeutics Ltd., Edinburgh, Scotland, UK.
Nicole PolinskiThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Shima Rastegar-PouyaniMemory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Alastair D ReithBreckenfield Consulting Ltd., London, UK.
Ekemini RileyCoalition for Aligning Science, Chevy Chase, MD, USA.
Lee RubinDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Mina RytenUK Dementia Research Institute and Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Jessica SadickValo Health Inc., Lexington, MA, USA.
Tina SchwabeNine Square Therapeutics, South San Franscisco, CA, USA.
Todd ShererThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Sarah SilvergleidSchrödinger Inc., New York, NY, USA.
Andrew SingletonGlobal Parkinson's Genetics Program, Chevy Chase, MD, USA.
Lara St ClairThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Jan StoehrAbbVie, Cambridge, MA, USA.
David J StoneAbbVie, Cambridge, MA, USA.
Julianna SullivanThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Nicole TanenbaumDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
Elisa TinelliGolgi Neurosciences S.r.l, Milan, Italy.
Kate TrimbleThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Yifei WangDepartment of Nutritional Sciences and Toxicology, University of California, Berkeley, CA, USA.
Stacie WeningerF-Prime Capital Partners, Boston, MA, USA.
Nicolás WiggenhauserInterdepartmental Doctoral Program in Anthropological Sciences, Stony Brook University, Stony Brook, NY, USA.
Stephen WoodNeuron23 Inc., South San Franscisco, CA, USA.
Darryle SchoeppIndependent Pharmaceutical Research Consultant, Ardmore, PA, USA.
Virginie Buggia-PrevotValo Health Inc., Lexington, MA, USA.
Shalini PadmanabhanThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Gaia SkibinskiThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA. gskibinski@michaeljfox.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identifying effective therapeutic targets for Parkinson's disease (PD) is challenging, with no current disease-modifying therapies available. To address this, The Michael J. Fox Foundation for Parkinson's Research launched the Targets to Therapies (T2T) initiative, uniting experts to prioritize and validate promising targets. T2T aims to develop validation strategies, create comprehensive target data profiles, and build tools to support drug development, ultimately accelerating the discovery of new therapies for PD patients.

Identifiers

PMID40541945
PMCPMC12181325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.